Mechanisms of Oncogenesis Research Program

肿瘤发生机制研究进展 肿瘤发生机制(MOO)计划的目标是阐明去调控的遗传和 推动肿瘤发生和发展的表观遗传事件，并确定癌症相关的治疗靶点。 Moo由癌症信号和小鼠肿瘤模型专家Wu和肿瘤专家Renne领导 病毒学和非编码RNA。教育统筹处是一个由38名成员组成的多学科小组，代表19个部门。 来自5所大学。自2016年以来，招聘了20名教职员工，其中包括14名早期调查人员(ESIS)。 MOO的科学目标是：1)阐明遗传和表观遗传改变在癌症中的作用；2)确定 调控RNA在肿瘤发生中的作用；以及，3)将MOO的发现转化为新的治疗方法 接近了。与Aim 3一致，Guryanova发现DNMT3A突变体AML对 低剂量阿糖胞苷，这导致与Al-Mansour合作开发了一项治疗试验 (CTHR)，由基础科学和临床研究ADS和IIT智库培育。Moo有个同行- 审查直接成本为900万美元/年的资金基础(自2019年以来增加了10%)，代表59个同行审查 其中24个项目来自NCI(380万美元直接成本)，包括NCI P01、NIH和其他同行审查 消息来源。自2019年以来，已向新招聘的教育系统颁发了10项新的赠款。MOO培养内部和内部 通过工作组重点会议(表观遗传学、肿瘤病毒学和肺病毒学)进行程序性互动 癌症，集水区优先)，研讨会，和年度计划务虚会。这些互动导致了11个活跃的 多PI同行评审赠款和多机构NCI P01。Moo协作的成功也是 自2016年以来，762份与癌症相关的出版物证明了这一点，其中20%带有影响因素&>10。此外，19%的 出版物是跨方案的，23%是方案内的，74%是多机构的。Moo 成员还获得了36项新专利。Moo导师培训了162名研究生和71名博士后， 由45%的妇女和10%代表不足的少数族裔(URM)组成。有14名受训人员(9名女性；3名 URM)由美国国立卫生研究院培训补助金支持。吴担任社区外展的项目联络人，并 接洽(COE)。她和雷恩向社区成员传达了Moo研究的影响，作为回报， 了解他们的需求。雷恩与科合作，共同为公民开发了UFHCC癌症课程 科学家。MoO领导层和成员致力于通过以下方式增加多样性、公平性和包容性 参与招聘受训人员和教员，与多样性发展司协调和指导， 公平和包容。与战略计划《势头2027》相一致的未来目标将重点放在 范式转换基本发现和确定治疗靶点，目标是临床翻译 CTHR和CCPS成员解决CA中的癌症负担。MoO将加强以下领域的研究 肺癌和RNA生物学。UFCC将根据合作出版物、新的 方案和MPI赠款，以及MOO发现转化为临床。

MECHANISMS OF ONCOGENESIS PROGRAM: ABSTRACT The objectives of the Mechanisms of Oncogenesis (MOO) program are to elucidate the deregulated genetic and epigenetic events that drive tumor initiation and progression and to identify cancer relevant therapeutic targets. MOO is led by Wu, an expert in cancer signaling and mouse tumor models, and Renne, an expert in tumor virology and non-coding RNAs. MOO is a multidisciplinary group of 38 members, representing 19 departments from 5 colleges. Since 2016, 20 faculty, including 14 early stage investigators (ESIs) were recruited since 2016. The scientific aims of MOO are to: 1) elucidate the role of genetic and epigenetic alterations in cancer; 2) define the role of regulatory RNAs in oncogenesis; and, 3) translate MOO discoveries into novel therapeutic approaches. In alignment with Aim 3, Guryanova discovered that DNMT3A mutant AML was highly sensitive to low dose cytarabine, which has led to the development of a treatment trial in collaboration with Al-Mansour (CTHR), fostered by the ADs for Basic Sciences and Clinical Research and the IIT Think Tank. MOO has a peer- reviewed funding base of >$9M/yr in direct costs (increased >10% since 2019), representing 59 peer-reviewed projects of which 24 are from NCI ($3.8M direct costs), including an NCI P01, NIH, and other peer-reviewed sources. Since 2019, 10 new grants have been awarded to newly recruited ESIs. MOO cultivates intra- and inter- programmatic interactions through working group focused meetings (Epigenetics, Tumor Virology, and Lung Cancer, a catchment area priority), seminars, and annual program retreats. These interactions led to 11 active multi-PI peer-reviewed grants and a multi-institutional NCI P01. The success of MOO collaborations is also demonstrated by 762 cancer-related publications since 2016, 20% with impact factors >10. Moreover, 19% of publications are inter-programmatic, 23% are intra-programmatic, and 74% are multi-institutional. MOO members were also granted 36 new patents. MOO mentors trained 162 graduate students and 71 postdocs, comprised of 45% women and 10% underrepresented minorities (URM). There were 14 trainees (9 women; 3 URM) supported by NIH training grants. Wu serves as the program liaison to community outreach and engagement (COE). She and Renne convey the impact of MOO research to community members and, in return, learn about their needs. Renne, working with COE, co-developed the UFHCC cancer curriculum for Citizen Scientists. MOO leadership and members are committed to increase diversity, equity, and inclusion through participation in recruitment of trainees and faculty, in coordination with and guidance from the AD for Diversity, Equity, and Inclusion. Future goals, in alignment with the strategic plan, Momentum 2027, will be focused on paradigm shifting basic discovery and identification of therapeutic targets with the goal of clinical translation with CTHR and CCPS members to address the cancer burden in the CA. MOO will enhance research in the areas of lung cancer and RNA biology. UFHCC will monitor success based on collaborative publications, new programmatic and MPI grants, and MOO discoveries translated into the clinic.